デフォルト表紙
市場調査レポート
商品コード
1764277

セリアック病の世界市場レポート 2025年

Celiac Disease Global Market Report 2025


出版日
ページ情報
英文 175 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
セリアック病の世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

セリアック病市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1%で11億5,000万米ドルに成長します。予測期間中の成長は、個別化医療への需要の高まり、ヘルスケアインフラの拡大、栄養カウンセリングサービスへのニーズの高まり、小児科受診率の上昇、早期検診や予防対策への注目の高まりなどに起因すると考えられます。この期間に予想される主要動向には、診断検査の利用可能性の拡大、遺伝子検査技術の進歩、プライマリケアにおけるスクリーニングプロトコルの強化、ELISA法や血清学的検査法の革新、非侵襲的診断アプローチの採用などがあります。

個別化医療の拡大は、今後数年間のセリアック病市場の成長に大きく貢献すると予想されます。個別化医療は、個人の遺伝的体質、環境、ライフスタイルに合わせて医療を調整するヘルスケアアプローチです。個別化医療への需要が高まっている背景には、遺伝子検査へのアクセス性が高まっていることがあります。セリアック病の文脈では、個別化医療は遺伝子マーカーと特異的な免疫反応の正確な同定を可能にし、より的を絞った効果的な治療戦略をもたらします。例えば、2024年2月、米国の非営利団体である個別化医療連合(Personalized Medicine Coalition)は、FDAが2023年に希少疾患に対する個別化治療を16件承認し、2022年の6件から増加したと報告しました。このように、個別化医療の成長はセリアック病市場を前進させると予想されます。

セリアック病市場の主要企業は、抗インターロイキン15(IL-15)抗体など、過剰な免疫細胞の活性を制御することで組織損傷を最小限に抑える先進療法の開発に注力しています。抗インターロイキン15(IL-15)抗体は、IL-15サイトカインの作用を阻害する標的タンパク質であり、それによって免疫反応を調節し、炎症を抑えるのに役立っています。例えば、2025年5月、イスラエルに本社を置く製薬会社テバ・ファーマシューティカルインダストリーズは、米国食品医薬品局(FDA)が抗インターロイキン15(IL-15)抗体TEV-53408を治験薬としてファーストトラック指定したと発表しました。このモノクローナル抗体は、グルテン除去食を遵守しているにもかかわらず症状が続くセリアック病患者を対象に開発されています。TEV-53408は、セリアック病の腸管障害を引き起こす免疫反応の引き金となる重要な分子であるインターロイキン15(IL-15)を阻害することにより作用します。TEV-53408は現在、その安全性と有効性を評価するために第2a相臨床検査が行われています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場:金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のセリアック病:PESTEL分析(政治、社会、技術、環境、法的要因、促進要因と抑制要因)
  • 最終用途産業の分析
  • 世界のセリアック病市場:成長率分析
  • 世界のセリアック病市場の実績:規模と成長、2019~2024年
  • 世界のセリアック病市場の予測:規模と成長、2024~2029年、2034年
  • 世界のセリアック病:総潜在市場規模(TAM)

第6章 市場セグメンテーション

  • 世界のセリアック病市場:治療別、実績と予測、2019~2024年、2024~2029年、2034年
  • インフリキシマブ
  • ララゾチド酢酸塩
  • グルテンフリーダイエット
  • その他の治療
  • 世界のセリアック病市場:投与経路別、実績と予測、2019~2024年、2024~2029年、2034年
  • 経口
  • 非経口
  • 世界のセリアック病市場:エンドユーザー別、実績と予測、2019~2024年、2024~2029年、2034年
  • 病院
  • 在宅医療
  • その他
  • 世界のセリアック病市場、インフリキシマブのサブセグメンテーション、タイプ別、実績と予測、2019~2024年、2024~2029年、2034年
  • バイオシミラーインフリキシマブ
  • ブランド名インフリキシマブ
  • 静脈内投与
  • 病院での使用
  • 世界のセリアック病市場、ララゾチド酢酸塩のサブセグメンテーション、タイプ別、実績と予測、2019~2024年、2024~2029年、2034年
  • 臨床検査段階の製品
  • 経口カプセル製剤
  • 成人セリアック病患者
  • 小児研究用途
  • 単剤療法と併用療法
  • 世界のセリアック病市場、グルテンフリーダイエットのサブセグメンテーション、タイプ別、実績と予測、2019~2024年、2024~2029年、2034年
  • グルテンフリー包装食品
  • グルテンフリーベーカリー製品
  • グルテンフリースナック
  • グルテンフリー栄養補助食品
  • グルテンフリー飲料
  • 世界のセリアック病市場、その他の治療のサブセグメンテーション、タイプ別、実績と予測、2019~2024年、2024~2029年、2034年
  • コルチコステロイド
  • 免疫抑制薬
  • 酵素療法
  • モノクローナル抗体
  • プロバイオティクスとマイクロバイオームモジュレーター

第7章 地域別・国別分析

  • 世界のセリアック病市場:地域別、実績と予測、2019~2024年、2024~2029年、2034年
  • 世界のセリアック病市場:国別、実績と予測、2019~2024年、2024~2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • セリアック病市場:競合情勢
  • セリアック病市場:企業プロファイル
    • Pfizer Inc.
    • Sanofi SA
    • Novartis AG
    • Takeda Pharmaceutical Company Ltd.
    • Chugai Pharmaceutical Co. Ltd.

第31章 その他の大手企業と革新的企業

  • Dr Falk Pharma GmbH
  • Theriva Biologics Inc.
  • Equillium Inc.
  • Immunic Inc.
  • Barinthus BIoTherapeutics Plc
  • Allero Therapeutics
  • Anokion SA
  • Mozart Therapeutics
  • ImmunogenX
  • Topas Therapeutics GmbH
  • Parvus Therapeutics Inc.
  • AMYRA BIoTech AG
  • Provention Limited
  • Precigen Inc.
  • Zedira GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • セリアック病市場、2029年:新たな機会を提供する国
  • セリアック病市場、2029年:新たな機会を提供するセグメント
  • セリアック病市場、2029年:成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35865

Celiac disease is an autoimmune condition in which the ingestion of gluten triggers an immune response that damages the small intestine, resulting in malabsorption and a range of symptoms. Diagnosis is typically confirmed through blood tests and intestinal biopsy, and the only effective treatment is a lifelong gluten-free diet to promote intestinal healing and prevent complications.

The primary treatments for celiac disease include infliximab, larazotide acetate, gluten-free diets, and other options. Infliximab is a monoclonal antibody that reduces inflammation by inhibiting tumor necrosis factor-alpha (TNF-a). It can be administered via oral or parenteral routes and is used across various settings, including hospitals, home care, and other healthcare facilities.

The celiac disease market research report is one of a series of new reports from The Business Research Company that provides celiac disease market statistics, including celiac disease industry global market size, regional shares, competitors with a celiac disease market share, detailed celiac disease market segments, market trends and opportunities, and any further data you may need to thrive in the celiac disease industry. This celiac disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The celiac disease market size has grown rapidly in recent years. It will grow from $0.71 billion in 2024 to $0.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. Growth during the historic period can be attributed to the increasing prevalence of celiac disease, greater awareness of gluten-related disorders, rising research funding for autoimmune conditions, a surge in food allergies and sensitivities, and a growing emphasis on consumer health consciousness.

The celiac disease market size is expected to see rapid growth in the next few years. It will grow to $1.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The projected growth in the forecast period can be attributed to the increasing demand for personalized medicine, expansion of healthcare infrastructure, growing need for nutritional counseling services, rising rates of pediatric diagnoses, and a greater focus on early-life screening and preventive measures. Key trends expected during this period include wider availability of diagnostic testing, advancements in genetic testing technologies, enhanced screening protocols in primary care, innovations in ELISA and serological testing methods, and the adoption of non-invasive diagnostic approaches.

The expansion of personalized medicine is expected to contribute significantly to the growth of the celiac disease market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatment to an individual's genetic makeup, environment, and lifestyle. The rising demand for personalized medicine is driven by the growing accessibility of genetic testing, which facilitates more accurate diagnoses and personalized treatment plans based on individual patient profiles. In the context of celiac disease, personalized medicine enables precise identification of genetic markers and specific immune responses, resulting in more targeted and effective treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growth of personalized medicine is expected to propel the celiac disease market forward.

Leading companies in the celiac disease market are concentrating on the development of advanced therapies, such as anti-interleukin-15 (IL-15) antibodies, to minimize tissue damage by regulating excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are targeted proteins that block the action of the IL-15 cytokine, thereby helping to modulate immune responses and reduce inflammation. For example, in May 2025, Teva Pharmaceutical Industries, a pharmaceutical company based in Israel, announced that the U.S. Food and Drug Administration had granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This monoclonal antibody is being developed for patients with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. It works by inhibiting interleukin-15 (IL-15), a key molecule responsible for triggering the immune response that causes intestinal damage in celiac disease. TEV-53408 is currently being evaluated in a Phase 2a clinical trial to assess its safety and efficacy.

In May 2025, Targeted Genomics, a US-based company specializing in celiac disease genetics and wellness, entered into a partnership with OraSure Technologies to provide direct-to-consumer (DTC) genetic testing for celiac disease. This collaboration allows Targeted Genomics to work alongside an experienced industry leader to advance their mission. The partnership reinforces their goal of delivering genetic risk information directly to individuals who are proactive about their health. OraSure Technologies is a US-based company that offers diagnostic solutions for celiac disease.

Major players in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in celiac disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the celiac disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The celiac disease market consists of revenues earned by entities by providing services such as diagnostic testing services, histopathology services, dietary consultation, nutrition counseling, and food certification. The market value includes the value of related goods sold by the service provider or included within the service offering. The celiac disease market also includes sales of gluten-free foods, diagnostic test kits, nutritional supplements, gluten detection devices, and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Celiac Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on celiac disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for celiac disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The celiac disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Infliximab; Larazotide Acetate; Gluten Free Diet; Other Treatments
  • 2) By Route Of Administration: Oral; Parenteral
  • 3) By End Users: Hospitals; Homecare; Other End-Users
  • Subsegments:
  • 1) By Infliximab: Biosimilar Infliximab; Branded Infliximab; Intravenous Administration; Hospital-Based Usage; Off-Label Use In Refractory Celiac Disease;
  • 2) By Larazotide Acetate: Clinical Trial Phase Products; Oral Capsule Formulation; Adult Celiac Patients; Pediatric Investigational Use; Monotherapy And Combination Therapy
  • 3) By Gluten Free Diet: Packaged Gluten-Free Foods; Gluten-Free Bakery Products; Gluten-Free Snacks; Gluten-Free Nutritional Supplements; Gluten-Free Beverages
  • 4) By Other Treatments: Corticosteroids; Immunosuppressive Drugs; Enzyme Therapies; Monoclonal Antibodies; Probiotics And Microbiome Modulators
  • Companies Mentioned: Pfizer Inc.; Sanofi SA; Novartis AG; Takeda Pharmaceutical Company Ltd.; Chugai Pharmaceutical Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Celiac Disease Market Characteristics

3. Celiac Disease Market Trends And Strategies

4. Celiac Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Celiac Disease Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Celiac Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Celiac Disease Market Growth Rate Analysis
  • 5.4. Global Celiac Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Celiac Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Celiac Disease Total Addressable Market (TAM)

6. Celiac Disease Market Segmentation

  • 6.1. Global Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infliximab
  • Larazotide Acetate
  • Gluten Free Diet
  • Other Treatments
  • 6.2. Global Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • 6.3. Global Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Other End-Users
  • 6.4. Global Celiac Disease Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biosimilar Infliximab
  • Branded Infliximab
  • Intravenous Administration
  • Hospital-Based Usage
  • 6.5. Global Celiac Disease Market, Sub-Segmentation Off-Label Use In Refractory Celiac Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Of Larazotide Acetate, By Type
  • Clinical Trial Phase Products
  • Oral Capsule Formulation
  • Adult Celiac Patients
  • Pediatric Investigational Use
  • Monotherapy and Combination Therapy
  • 6.6. Global Celiac Disease Market, Sub-Segmentation Of Gluten Free Diet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Packaged Gluten-Free Foods
  • Gluten-Free Bakery Products
  • Gluten-Free Snacks
  • Gluten-Free Nutritional Supplements
  • Gluten-Free Beverages
  • 6.7. Global Celiac Disease Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Corticosteroids
  • Immunosuppressive Drugs
  • Enzyme Therapies
  • Monoclonal Antibodies
  • Probiotics And Microbiome Modulators

7. Celiac Disease Market Regional And Country Analysis

  • 7.1. Global Celiac Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Celiac Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Celiac Disease Market

  • 8.1. Asia-Pacific Celiac Disease Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Celiac Disease Market

  • 9.1. China Celiac Disease Market Overview
  • 9.2. China Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Celiac Disease Market

  • 10.1. India Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Celiac Disease Market

  • 11.1. Japan Celiac Disease Market Overview
  • 11.2. Japan Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Celiac Disease Market

  • 12.1. Australia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Celiac Disease Market

  • 13.1. Indonesia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Celiac Disease Market

  • 14.1. South Korea Celiac Disease Market Overview
  • 14.2. South Korea Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Celiac Disease Market

  • 15.1. Western Europe Celiac Disease Market Overview
  • 15.2. Western Europe Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Celiac Disease Market

  • 16.1. UK Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Celiac Disease Market

  • 17.1. Germany Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Celiac Disease Market

  • 18.1. France Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Celiac Disease Market

  • 19.1. Italy Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Celiac Disease Market

  • 20.1. Spain Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Celiac Disease Market

  • 21.1. Eastern Europe Celiac Disease Market Overview
  • 21.2. Eastern Europe Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Celiac Disease Market

  • 22.1. Russia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Celiac Disease Market

  • 23.1. North America Celiac Disease Market Overview
  • 23.2. North America Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Celiac Disease Market

  • 24.1. USA Celiac Disease Market Overview
  • 24.2. USA Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Celiac Disease Market

  • 25.1. Canada Celiac Disease Market Overview
  • 25.2. Canada Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Celiac Disease Market

  • 26.1. South America Celiac Disease Market Overview
  • 26.2. South America Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Celiac Disease Market

  • 27.1. Brazil Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Celiac Disease Market

  • 28.1. Middle East Celiac Disease Market Overview
  • 28.2. Middle East Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Celiac Disease Market

  • 29.1. Africa Celiac Disease Market Overview
  • 29.2. Africa Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Celiac Disease Market Competitive Landscape And Company Profiles

  • 30.1. Celiac Disease Market Competitive Landscape
  • 30.2. Celiac Disease Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Celiac Disease Market Other Major And Innovative Companies

  • 31.1. Dr Falk Pharma GmbH
  • 31.2. Theriva Biologics Inc.
  • 31.3. Equillium Inc.
  • 31.4. Immunic Inc.
  • 31.5. Barinthus Biotherapeutics Plc
  • 31.6. Allero Therapeutics
  • 31.7. Anokion SA
  • 31.8. Mozart Therapeutics
  • 31.9. ImmunogenX
  • 31.10. Topas Therapeutics GmbH
  • 31.11. Parvus Therapeutics Inc.
  • 31.12. AMYRA Biotech AG
  • 31.13. Provention Limited
  • 31.14. Precigen Inc.
  • 31.15. Zedira GmbH

32. Global Celiac Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Celiac Disease Market

34. Recent Developments In The Celiac Disease Market

35. Celiac Disease Market High Potential Countries, Segments and Strategies

  • 35.1 Celiac Disease Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Celiac Disease Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Celiac Disease Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer